查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1963829

急性偏头痛药物市场－全球产业规模、份额、趋势、机会、预测：治疗方法、给药途径、通路、区域及竞争格局，2021-2031年

Acute Migraine Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球急性偏头痛治疗市场预计将从 2025 年的 23.2 亿美元成长到 2031 年的 31.1 亿美元，复合年增长率为 5.01%。

这些药物专为偏头痛发作初期使用而设计，可缓解疼痛及相关症状，如噁心和光敏感性。这与预防性治疗策略有所区别。市场成长的主要驱动因素是全球头痛疾病盛行率的不断上升，以及患者迫切需要快速起效的治疗方法，以便尽快恢復日常活动。此外，创新药物类别的推出，特别是抑钙素基因相关胜肽受体拮抗剂和地坦类药物，也是重要的推动因素，为对传统曲坦类药物不耐受或无反应的患者提供了有效的治疗选择。

市场概览
预测期 2027-2031
市场规模：2025年 23.2亿美元
市场规模：2031年 31.1亿美元
复合年增长率：2026-2031年 5.01%
成长最快的细分市场 医院药房
最大的市场 北美洲

儘管取得了这些积极进展，但仍存在许多重大障碍，例如诊断不足以及围绕这种疾病的社会污名，这些都限制了患者获得处方级治疗的机会。由于缺乏临床检验或无法获得专业的医疗服务，许多患者被迫依赖非处方药。根据欧洲偏头痛和头痛联盟2024年的数据，74%的偏头痛患者认为医疗专业人员没有认真对待他们的症状。患者与医疗服务提供者之间持续存在的这种认知差距，是推广先进急性治疗方案的主要障碍，并阻碍了整个市场的成长。

市场驱动因素

新型抑钙素基因相关胜肽 (CGRP) 受体拮抗剂和 5-HT1F促效剂的出现是推动市场成长的主要动力，从根本上改变了对标准曲坦类药物无反应患者的治疗格局。这些先进疗法，包括口服吉泮和地坦，凭藉其疗效和卓越的心血管安全性，填补了重要的治疗空白，并在大型医疗系统中广泛应用。这些针对特异性机制的治疗方法之所以受到青睐，是因为它们能够在缓解疼痛的同时，避免传统治疗标准中固有的血管收缩风险。领先的创新企业也反映了这项商业性成功；例如，辉瑞公司于 2024 年 10 月发布的 2024 年第三季财报显示，其 CGRP标靶治疗Nurtec ODT/Vydura 的全球营收成长了 45%，凸显了市场对这些先进治疗方法的强劲需求。

同时，全球偏头痛发病率和盛行率的不断上升，导致对治疗方案的需求居高不下，并给公共卫生基础设施带来沉重负担。庞大的患者族群亟需便捷有效的急性治疗方案，以减轻偏头痛造成的失能。根据美国国立卫生研究院 (NIH) 于 2024 年 12 月发布的《全球偏头痛负担趋势》调查报告，预计全球偏头痛患者人数将激增至约 11.6 亿，其中女性受到的影响尤为显着。如此庞大的患者需求正在推动市场成长，同时也凸显了广泛应用治疗方法的必要性。正如艾伯维公司于 2024 年 10 月发布的《2024 年第三季财务业绩报告》所示，Hubre Ruby 的全球净销售额达到 2.69 亿美元，印证了这项由患病率上升趋势驱动的市场扩张。

市场挑战

偏头痛的污名化和诊断不足严重阻碍了急性治疗市场的成长，因为这导致患者需求与临床干预脱节。当偏头痛被轻描淡写地视为轻微症状或心理缺陷时，患者会将这些污名内化，并往往犹豫是否寻求专业医疗协助。因此，相当一部分患者依赖特异性处方药，而这些药物并未对处方药市场做出贡献。由此，诸如CGRP受体拮抗剂等先进疗法的潜在市场被人为地限制，因为治疗方法需要医生的诊断。

欧洲偏头痛与头痛联盟2024年的报告就是一个突出的例子，该报告指出，35%的偏头痛患者由于「害怕尴尬或受到批评」而延迟或避免就医。这项统计数据揭示了一个显着的差距：由于社会和医疗方面的污名化，潜在的急性治疗使用者流失。由于迴避临床环境，这些患者实际上被排除在专业急性治疗药物的商业市场之外，直接降低了新治疗层级的整体成长潜力和普及率，儘管这些疗法已被证明有效。

市场趋势

快速起效的鼻内吸入系统正成为一股重要的发展趋势。这些系统旨在克服口服药物治疗在治疗胃肠道麻痹和伴随严重噁心的偏头痛患者方面的局限性。这些创新製剂可绕过胃肠道，确保药物稳定吸收并加速起效。这对于口服给药无效的严重偏头痛发作至关重要。该领域的一项重大进展是Dihydroergotamine鼻粉製剂STS101近期获得监管部门批准。根据2024年11月NeurologyLive的报告“Satsuma公司重新提交STS101鼻粉的新药申请”，ASCEND试验的临床数据显示，34.2%的患者在两小时内疼痛得到缓解，这支持了该给药方式在改善急性治疗效果方面的潜力。

同时，市场格局正在重塑，针对单药治疗效果不佳的患者，推出了曲坦类药物和非类固醇消炎剂（NSAIDs）的固定剂量组合药物。这些复方製剂针对不同的病理机制—抑制5-羟色胺受体并同时减轻神经发炎—从而产生协同的临床疗效和持续缓解。新型双机制口服疗法AXS-07的研发便是这项创新的最佳例证。根据Axsome Therapeutics公司2024年4月发布的公告，“新的汇总数据显示AXS-07疗效显着”，23%的患者在服用该复方製剂两小时内偏头痛疼痛得到缓解，显着高于安慰剂组的11%。这证实了这种综合疗法的临床优势。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：急性偏头痛药物的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 治疗方法（预防性药物、止痛药）
    • 给药途径（口服、注射、鼻喷雾、其他）
    • 分销通路（医院药局、零售药局、网路药局）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美急性偏头痛药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲急性偏头痛药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区急性偏头痛药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲急性偏头痛药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲急性偏头痛药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球急性偏头痛药物市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Endo International PLC
  • AbbVie Inc.
  • Impax Laboratories LLC
  • Glaxo Smith Kline PLC
  • Astellas Pharma Inc
  • Amgen Inc
  • Bayer AG
  • AstraZeneca PLC
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Pfizer Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17586

The Global Acute Migraine Drugs Market is projected to expand from USD 2.32 Billion in 2025 to USD 3.11 Billion by 2031, registering a CAGR of 5.01%. These pharmaceutical interventions are specifically designed for administration at the beginning of a migraine attack to mitigate pain and associated symptoms like nausea and light sensitivity, separating them from preventive strategies. Market growth is largely underpinned by the increasing global incidence of debilitating headache disorders and the pressing need for fast-acting treatments that allow patients to resume daily activities. Furthermore, the introduction of innovative drug classes, particularly calcitonin gene-related peptide receptor antagonists and ditans, serves as a significant catalyst by offering viable options for individuals who cannot tolerate or do not respond to traditional triptan medications.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.32 Billion
Market Size 2031USD 3.11 Billion
CAGR 2026-20315.01%
Fastest Growing SegmentHospital Pharmacies
Largest MarketNorth America

Despite these positive developments, the market encounters substantial obstacles stemming from the underdiagnosis and social stigma attached to the condition, which restricts access to prescription-grade therapies. Many patients depend on over-the-counter remedies because they lack clinical validation or access to specialized healthcare services. Data from the European Migraine & Headache Alliance in 2024 indicates that 74% of migraine sufferers felt medical professionals failed to take their condition seriously. This persistent disconnect between patients and healthcare providers represents a critical barrier that curtails the uptake of advanced acute treatments and hampers broader market growth.

Market Driver

The emergence of novel calcitonin gene-related peptide (CGRP) receptor antagonists and 5-HT1F agonists is a primary force accelerating market growth, fundamentally altering the treatment landscape for those who do not respond to standard triptans. These advanced pharmacotherapies, including oral gepants and ditans, fill a critical therapeutic void by delivering efficacy alongside superior cardiovascular safety profiles, encouraging widespread adoption within major healthcare systems. The transition toward these mechanism-specific treatments is fueled by their capacity to offer pain freedom without the vasoconstrictive risks inherent in older care standards. Leading innovators reflect this commercial success; for instance, Pfizer's 'Third-Quarter 2024 Earnings Release' in October 2024 reported a 45% global increase in operational revenues for its CGRP-targeted therapy, Nurtec ODT/Vydura, highlighting the strong demand for these sophisticated interventions.

Simultaneously, the increasing global incidence and prevalence of migraine disorders maintain high demand for therapeutic solutions, placing significant pressure on public health infrastructures. The magnitude of the affected population requires accessible and effective acute care options to alleviate the disability caused by the condition. According to the 'Global Trends in Migraine Burden' study by the National Institutes of Health in December 2024, global migraine cases have surged to approximately 1.16 billion, with a disproportionate impact on female individuals. This extensive patient need translates into substantial market value and underscores the requirement for widely available treatments, as evidenced by AbbVie's 'Third-Quarter 2024 Financial Results' in October 2024, which showed global net revenues for Ubrelvy reaching $269 million, confirming the sector's expansion driven by these prevalence dynamics.

Market Challenge

The stigmatization and underdiagnosis of migraine serve as major impediments to the growth of the acute drug market by disconnecting patient needs from clinical intervention. When migraine is dismissed as a minor complaint or a psychological weakness, patients frequently internalize this bias and hesitate to seek professional medical assistance. This reluctance causes a significant segment of the patient population to rely on non-specific, over-the-counter medications that do not contribute to the prescription pharmaceutical sector. As a result, the addressable market for advanced therapeutics, such as CGRP receptor antagonists, is artificially restricted since these treatments necessitate a physician's diagnosis.

Highlighting this issue, the European Migraine & Headache Alliance reported in 2024 that 35% of individuals with migraine admitted to delaying or avoiding medical advice due to embarrassment and fear of judgment. This statistic reveals a critical gap wherein potential users of acute therapies are lost to societal and medical stigma. By staying away from clinical environments, these patients are effectively removed from the commercial market for specialized acute drugs, which directly reduces the overall growth potential and adoption rates of new therapeutic classes, despite their proven efficacy.

Market Trends

The advancement of rapid-onset intranasal and inhalation delivery systems is emerging as a significant trend, specifically engineered to overcome the limitations of oral pharmacotherapy for patients experiencing migraine-associated gastroparesis and severe nausea. By bypassing the gastrointestinal tract, these innovative formulations ensure consistent drug absorption and accelerate therapeutic onset, which is crucial for debilitating attacks where oral administration proves ineffective. A key development in this area is the progress of STS101, a dihydroergotamine nasal powder that recently navigated regulatory steps; according to a November 2024 NeurologyLive report titled 'Satsuma Resubmits NDA Over STS101 Nasal Powder,' clinical data from the ASCEND trial showed that 34.2% of patients achieved pain freedom within two hours, underscoring the potential of this delivery method to enhance acute outcomes.

Concurrently, the market is being reshaped by the introduction of fixed-dose combination therapies that merge triptans with NSAIDs to provide multimodal mechanisms of action for patients with insufficient responses to monotherapy. These unified formulations target distinct pathogenic pathways-inhibiting serotonin receptors while simultaneously reducing neuroinflammation-to yield synergistic clinical benefits and sustained relief. This innovation is best illustrated by the development of AXS-07, a novel dual-mechanism oral therapeutic; as announced by Axsome Therapeutics in April 2024 under 'New Pooled Data Highlights Efficacy of AXS-07,' the combination treatment enabled 23% of patients to achieve freedom from migraine pain at two hours compared to 11% in the placebo group, confirming the clinical superiority of this integrated approach.

Key Market Players

  • Endo International PLC
  • AbbVie Inc.
  • Impax Laboratories LLC
  • Glaxo Smith Kline PLC
  • Astellas Pharma Inc
  • Amgen Inc
  • Bayer AG
  • AstraZeneca PLC
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Pfizer Inc

Report Scope

In this report, the Global Acute Migraine Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Migraine Drugs Market, By Treatment

  • Preventive
  • Pain Relieving

Acute Migraine Drugs Market, By Route of Administration

  • Oral
  • Injectable
  • Nasal Sprays
  • Others

Acute Migraine Drugs Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Acute Migraine Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acute Migraine Drugs Market.

Available Customizations:

Global Acute Migraine Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acute Migraine Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Preventive, Pain Relieving)
    • 5.2.2. By Route of Administration (Oral, Injectable, Nasal Sprays, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Acute Migraine Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Acute Migraine Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Acute Migraine Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Acute Migraine Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Acute Migraine Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Acute Migraine Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Acute Migraine Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Acute Migraine Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Acute Migraine Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Acute Migraine Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Acute Migraine Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Acute Migraine Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Acute Migraine Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Acute Migraine Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Acute Migraine Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Acute Migraine Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Acute Migraine Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Acute Migraine Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Acute Migraine Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Acute Migraine Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Acute Migraine Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Acute Migraine Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Acute Migraine Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Acute Migraine Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Acute Migraine Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Endo International PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AbbVie Inc.
  • 15.3. Impax Laboratories LLC
  • 15.4. Glaxo Smith Kline PLC
  • 15.5. Astellas Pharma Inc
  • 15.6. Amgen Inc
  • 15.7. Bayer AG
  • 15.8. AstraZeneca PLC
  • 15.9. Dr. Reddy's Laboratories Ltd
  • 15.10. Eli Lilly and Company
  • 15.11. Pfizer Inc

16. Strategic Recommendations

17. About Us & Disclaimer